Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefiderocol in Hospitalized Pediatric Patients
NCT04215991Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of cefiderocol in Gram-negative bacterial infection, complicated urinary tract infection (cUTI), hospital-acquired bacterial pneumonia (HAP) and 1 more (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Adverse Events at 28 days, Maximum Observed Plasma Concentration at 8 hours and 3 more. Started Feb 2020; status: completed.
02
Drugs
cefiderocol
03
Conditions
Gram-negative bacterial infectioncomplicated urinary tract infection (cUTI)hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT04215991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215991.